Skip Navigation


Alcohol and Alcoholism Advance Access originally published online on December 13, 2004
Alcohol and Alcoholism 2005 40(2):151-154; doi:10.1093/alcalc/agh127
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
40/2/151    most recent
agh127v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by COCHRANE, M.
Right arrow Articles by ASHTON, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by COCHRANE, M.
Right arrow Articles by ASHTON, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Alcohol & Alcoholism Vol. 40, No. 2 © Medical Council on Alcohol 2005; all rights reserved

CASE REPORT

ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF WERNICKE–KORSAKOFF SYNDROME–THREE FURTHER CASES SHOW RESPONSE TO DONEPEZIL

MURRAY COCHRANE, ASHLEY COCHRANE, PRAMOD JAUHAR* and ELIZABETH ASHTON

Parkhead Hospital, 81 Salamanca Street, Glasgow, G31 5ES, UK

* Author to whom correspondence should be addressed at: Parkhead Hospital, 81 Salamanca Street, Glasgow, G31 5ES, UK. Tel: +44(0)141 211 8359; Fax: +44(0)141 211 8431. E-mail: Pramod.Jauhar{at}glacomen.scot.nhs.uk

(Received 23 April 2004; first review notified 5 June 2004; accepted in revised form 1 November 2004)

Three patients diagnosed with Wernicke–Korsakoff syndrome were treated with the acetylcholinesterase inhibitor, donepezil, for periods of 6 to 8 months. Cognitive testing [Alzheimer's disease assessment scale–cognitive subscale (ADAS–Cog), Mini-mental state examination (MMSE), Clock drawing test and six item 2 min recall] and carer questionnaires [Informant Questionnaire (IQ Code), Neuropsychiatric inventory scale (NPI)] were performed at baseline, mid- and endpoint of the treatment period and post-discontinuation. Progressive partial improvement occurred in cognitive measurements through the treatment period, some of which was sustained after discontinuing donepezil. Carer questionnaires also indicated improvement. Confounding factors necessitate caution when attributing improvements to the medication, but these cases suggest that this option merits further investigation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Alcohol AlcoholHome page
H. J. Luykx, L. D. A. Dorresteijn, P. M. J. Haffmans, A. Bonebakker, M. Kerkmeer, and V. M. Hendriks
Rivastigmine in Wernicke-Korsakoff's syndrome: Five patients with rivastigmine showed no more improvement than five patients without rivastigmine
Alcohol Alcohol., January 1, 2008; 43(1): 70 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
A. D. THOMSON and E. J. MARSHALL
THE NATURAL HISTORY AND PATHOPHYSIOLOGY OF WERNICKE'S ENCEPHALOPATHY AND KORSAKOFF'S PSYCHOSIS
Alcohol Alcohol., March 1, 2006; 41(2): 151 - 158.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.